Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$19.70 -2.6%	$16.97	$5.90 ▼ $23.64	$4.66B	0.6	3.35 million shs	2.18 million shs
GPCR Structure Therapeutics	$20.00 -1.7%	$24.48	$19.39 ▼ $62.74	$1.15B	-2.37	830,375 shs	996,045 shs
PTCT PTC Therapeutics	$55.31 -1.7%	$50.59	$24.00 ▼ $58.38	$4.36B	0.66	735,798 shs	613,290 shs
RNA Avidity Biosciences	$32.05 -0.2%	$31.39	$21.56 ▼ $56.00	$3.85B	1.02	1.32 million shs	1.58 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-2.57%	-4.42%	+26.93%	+10.12%	+203.08%
GPCR Structure Therapeutics	-1.67%	-11.39%	-4.90%	-32.30%	-52.57%
PTCT PTC Therapeutics	-1.71%	-2.93%	+10.58%	+20.66%	+97.82%
RNA Avidity Biosciences	-0.16%	+1.04%	+4.98%	+2.99%	+33.26%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	2.4311 of 5 stars	2.6	1.0	0.0	4.0	1.7	1.9
GPCR Structure Therapeutics	2.2782 of 5 stars	3.5	1.0	0.0	3.3	1.7	0.6
PTCT PTC Therapeutics	3.4924 of 5 stars	3.3	1.0	4.4	3.3	0.8	0.0
RNA Avidity Biosciences	2.3384 of 5 stars	4.5	1.0	0.0	2.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.25	Buy	$22.50	14.21% Upside
GPCR Structure Therapeutics	3.00	Buy	$81.29	306.43% Upside
PTCT PTC Therapeutics	2.53	Moderate Buy	$64.00	15.71% Upside
RNA Avidity Biosciences	3.00	Buy	$66.69	108.09% Upside

Current Analyst Ratings Breakdown

Latest GPCR, ADMA, PTCT, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/17/2025	RNA Avidity Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/17/2025	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
3/17/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
3/14/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$72.00 ➝ $78.00
3/13/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
3/12/2025	RNA Avidity Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$72.00
3/11/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$41.00 ➝ $55.00
3/10/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $48.00
3/7/2025	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$67.00 ➝ $70.00
3/7/2025	PTCT PTC Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$55.00
3/7/2025	RNA Avidity Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$70.00

(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.92	$0.06 per share	311.70	$0.60 per share	32.83
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
PTCT PTC Therapeutics	$806.78M	5.41	$2.66 per share	20.80	($10.85) per share	-5.10
RNA Avidity Biosciences	$10.90M	353.56	N/A	N/A	$6.76 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	-$28.24M	$0.82	70.36	28.55	N/A	17.80%	53.20%	26.07%	5/8/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.79	N/A	N/A	N/A	N/A	-16.37%	-15.68%	5/8/2025 (Estimated)
PTCT PTC Therapeutics	-$626.60M	-$4.73	N/A	N/A	N/A	-50.32%	N/A	-16.44%	4/24/2025 (Estimated)
RNA Avidity Biosciences	-$212.22M	-$2.89	N/A	N/A	N/A	-2,772.45%	-27.66%	-24.56%	5/8/2025 (Estimated)

Latest GPCR, ADMA, PTCT, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	PTCT PTC Therapeutics	$0.85	N/A	N/A	N/A	$437.16 million	N/A
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A
2/27/2025	Q4 2024	RNA Avidity Biosciences	-$0.76	-$0.80	-$0.04	-$0.80	$1.74 million	$2.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.48	7.09	3.26
GPCR Structure Therapeutics	N/A	27.63	27.63
PTCT PTC Therapeutics	N/A	2.10	2.04
RNA Avidity Biosciences	N/A	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
GPCR Structure Therapeutics	91.78%
PTCT PTC Therapeutics	N/A
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
GPCR Structure Therapeutics	9.43%
PTCT PTC Therapeutics	5.50%
RNA Avidity Biosciences	3.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	236.39 million	227.64 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
PTCT PTC Therapeutics	1,410	78.87 million	72.88 million	Optionable
RNA Avidity Biosciences	190	120.21 million	114.92 million	Optionable

GPCR, ADMA, PTCT, and RNA Headlines

Recent News About These Companies

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs

March 26 at 10:17 AM | seekingalpha.com

How Is Avidity Biosciences Inc. (NASDAQ:RNA) Positioned in the Biotech Sector?

March 26 at 8:46 AM | kalkinemedia.com

EFG Asset Management North America Corp. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

March 26 at 5:50 AM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?

March 25 at 4:20 PM | marketbeat.com

Cibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

March 25 at 3:53 AM | marketbeat.com

Swiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

March 25 at 3:35 AM | marketbeat.com

198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.

March 25 at 3:20 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $979,632.40 in Stock

March 24 at 4:05 AM | americanbankingnews.com

Magnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)

March 23, 2025 | marketbeat.com

Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $66.69

March 23, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in Stock

March 22, 2025 | marketbeat.com

Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 9,578 Shares of Stock

March 22, 2025 | marketbeat.com

Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 31,540 Shares of Stock

March 22, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 7,935 Shares

March 22, 2025 | insidertrades.com

Intech Investment Management LLC Increases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)

March 22, 2025 | marketbeat.com

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2025 | prnewswire.com

Proficio Capital Partners LLC Makes New $1.76 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)

March 20, 2025 | marketbeat.com

Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy

March 19, 2025 | managedhealthcareexecutive.com

Avidity Biosciences (NASDAQ:RNA) Shares Down 7.9% - Time to Sell?

March 19, 2025 | marketbeat.com

Scotiabank Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

March 19, 2025 | markets.businessinsider.com

HC Wainwright Reiterates Buy Rating for Avidity Biosciences (NASDAQ:RNA)

March 19, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, ADMA, PTCT, and RNA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$19.70 -0.52 (-2.57%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$19.75 +0.05 (+0.25%)

As of 08:55 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Structure Therapeutics NASDAQ:GPCR

$20.00 -0.34 (-1.67%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$20.20 +0.20 (+1.00%)

As of 08:00 AM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

PTC Therapeutics NASDAQ:PTCT

$55.31 -0.96 (-1.71%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$55.72 +0.41 (+0.75%)

As of 03/26/2025 06:46 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences NASDAQ:RNA

$32.05 -0.05 (-0.16%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$31.86 -0.19 (-0.60%)

As of 09:28 AM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time